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Dan L. Longo is professor of medicine at Harvard Medical School in the division of hematology at Brigham and
Women’s Hospital and Deputy Editor of the New England Journal of Medicine. He is a Master of the American
College of Physicians and is a member of the American Society of Clinical Investigation and the Association of
American Physicians. He has been active in research on the treatment of malignant lymphoma including new
treatments targeting CD30, CD40, HLA Class II molecules and immunoglobulin idiotype. His laboratory work has
focused in part on the regulation of lymphocyte proliferation, NK cell effects on hematopoiesis, and tumor-induced
immunosuppression. He is the Section Editor of the Malignant hematological diseases section for BMC Hematology.
In this interview, he explains how he first became interested in hematology and gives his personal view on the
recent progress and future challenges of the hematological cancer field in particular.How did you first become interested in
hematology?
I was exposed to outstanding hematologists in medical
school who were also great teachers, Patrick Henry,
Charles Mengel, and Victor Herbert. I found the subject
interesting and the patients fascinating. Looking at periph-
eral blood smears and bone marrow specimens was aes-
thetically pleasing as well as intellectually challenging. I
had the opportunity to work in Dr. Herbert’s laboratory
during my senior year and his amazing depth and breadth
of knowledge and innovative research ideas got me hooked
on the notion of an academic career in hematology.How did you end up focusing on malignant
hematological diseases?
After my training in internal medicine at the Brigham in
Boston, I went to the National Cancer Institute where
Vincent DeVita, Robert Young, and Bruce Chabner
played a major role in teaching me about cancer in gen-
eral and hematologic malignancies in particular. It was
the mid-1970’s and the curability of lymphomas with
chemotherapy had just been established and knowledge
of immunology was beginning to burgeon. The amazing
diversity of lymphocyte phenotypes was becomingCorrespondence: longod@grc.nia.nih.gov
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reproduction in any medium, provided the orapparent and the notion of lymphomas as tumors of
specific types of lymphocytes began to emerge from
work from Lee Nadler, Sam Broder, and others. I was
fortunate to collaborate with Stan Korsmeyer at NCI in
his studies on bcl2 in follicular lymphoma. Hybridoma
technology made it possible to develop an almost unlim-
ited supply of targeted therapies. It seemed that empiric
treatment success was being complemented by increas-
ing biologic insights and new treatment approaches were
being created—new drugs, monoclonal antibodies, im-
mune therapies. It felt like we were at the beginning of a
revolution in lymphoma treatment. And advances in
lymphoma treatment had led the way to advances in
treating other types of cancers. I wanted to be a part of
that expansion of the therapeutic armamentarium based
on the rational selection of targets.
Why is it an exciting time to be involved with
hematological cancer research in particular?
Remarkable progress is being made in elucidating molecu-
lar mechanisms involved in tumor biology and defining
tumor cell vulnerabilities. Many new therapies are
showing promising antitumor effects: proteasome in-
hibitors and lenalidomide in myeloma, arsenic and
transretinoic acid in promyelocytic leukemia, alk
inhibitors in anaplastic large cell lymphoma, BRAF
inhibitors in hairy cell leukemia, new third generation abl
kinase inhibitors in chronic myeloid leukemia, Bruton’shis is an Open Access article distributed under the terms of the Creative
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adoptive transfer of lymphocytes with chimeric antigen
receptors engineered to recognize tumors of various types,
and this list is not complete. Genetic lesions in virtually
every form of hematologic malignancy have been identi-
fied and although much more knowledge needs to be
developed, rational therapeutic targets have not all been
explored. New ways of interfering with driver mutations
and new ways of replacing essential functions damaged by
mutation in tumor cells are being assessed. For the fore-
seeable future, research on hematologic cancer will be
leading to new therapies and combinations of therapies to
further improve survival.
What do you think are the future directions of
research into this field?
We cannot let the partial success of novel interventions
targeting abnormal enzymes blind us to the prior
successes achieved by chemotherapeutic agents. I think
the future will involve several areas for progress:
continued definition of molecular targets for interven-
tion, better definition of prognostic subsets of patients
based on molecular features, use of the newer targeting
agents in combination with each other and with cancer
chemotherapeutic agents to achieve even better long-
term survival and cure, elucidation of host-tumor
interactions and their alteration to boost host defenses,
immunologic and vaccine approaches to treatment and
prevention, increased attention to late effects of treat-
ment and their prevention.
What challenges and developments can we
expect to see in the next few years?
A major challenge is the requirement for national and
international collaboration to take the next steps. Many
hematologic malignancies have quite high rates of re-
sponse and control with existing therapies. Studies to
show an improvement from 60% to 80% long-term
survival require more subjects than studies to show an
improvement from 15% to 35% long-term survival.
Furthermore, the many (and increasing) treatment choices
complicate study design. The numbers of patients
required for meaningful clinical trials and the abundant
ideas for novel therapies and their integration into stand-
ard treatments represent an enormous challenge to the
field. It is my hope that researchers can come together to
work collaboratively to take the treatment of hematologic
malignancies to next level of success.
What does the future hold for the field of
hematological cancer and what do you think are
its limitations?
It is my expectation that the field will continue to make
substantial improvements in the treatment of patientswith hematologic malignancies. It is expected that there
will be setbacks. Tumors adapt. Resistance may develop.
But it is hoped that the insights that emerge from study-
ing resistance will provide clues to overcoming it in the
next generation of treatments. We must also keep in
mind the remarkable heterogeneity in tumor cells. A
fundamental insight in cancer 50 years ago was its clonal
origins. However, until recently, the wide array of
genotypes that evolve in a tumor over time was not fully
appreciated. We will have to be careful to choose thera-
peutic targets that are likely shared by all the tumor cells
rather than alterations in clonal variants that account for
a small fraction of the tumor.
Are there any particular papers you would like to
see submitted to your section?
We hope the journal becomes a venue for interesting
new findings including relevant basic science insights
and clinical applications. Well-done negative clinical
trials may also help us take the next step and should be
considered if the result is an important addition to the
knowledge base.
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